Background: Global tuberculosis (TB) eradication efforts are hampered by the vast reservoir of persons with latent TB infection (LTBI). Although the lifetime risk of reactivation is 5-10% among immune competent persons, HIV-infected persons have a ~10% annual risk of reactivation. For this reason, it is recommended that those with HIV infection are tested for LTBI and treated if positive. However, currently available regimens are lengthy (daily isoniazid for 9 months) or pose significant drug-drug interactions with antiretroviral therapy (rifampin for 4 months). Therefore, new strategies to treat LTBI, especially in the setting of HIV co-infection, are urgently needed. A major obstacle to this end is our limited understanding of how Mycobacterium tuberculosis (Mtb) is able to persist in the infected host for years or even decades, exhibiting tolerance to anti-TB drugs. The traditional view is that LTBI represents a paucibacillary population of non-replicating organisms with reduced metabolism, likely as an adaptive response to the unfavorable milieu within caseous granulomas. Several regulatory pathways, including the stringent response, have been implicated in bacillary growth arrest and phenotypic drug tolerance. Challenging this classical paradigm, recent studies using clinically relevant animal models have reported accumulation of Mtb mutations during LTBI, suggesting continued bacillary replication, while other studies have highlighted the importance of bacterial efflux pumps in mediating mycobacterial antibiotic tolerance.
Conclusions: LTBI does not refer to a single entity, but rather represents an array of microbiological and immunohistological findings giving rise to a clinical spectrum spanning LTBI and active TB. An improved understanding of the host-pathogen interactions underlying LTBI is expected to yield: 1) Novel potential drug targets for persistent bacilli, with the goal of shortening the duration of TB chemotherapy; 2) Novel diagnostic markers specific to the latent stage of infection and to reactivation disease; and 3) Novel attenuated vaccine candidates with an inability to reactivate, which is particularly important in the setting of HIV/AIDS.